AEterna Zentaris Company Profile (NASDAQ:AEZS)

About AEterna Zentaris

AEterna Zentaris logoAeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AEZS
  • CUSIP:
Key Metrics:
  • Previous Close: $3.35
  • 50 Day Moving Average: $2.92
  • 200 Day Moving Average: $3.47
  • 52-Week Range: $2.35 - $5.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.38
  • P/E Growth: 0.00
  • Market Cap: $39.09M
  • Outstanding Shares: 11,670,000
  • Beta: 1.68
Profitability:
  • Net Margins: -3,773.91%
  • Return on Equity: -213.27%
  • Return on Assets: -65.19%
Debt:
  • Current Ratio: 3.98%
  • Quick Ratio: 3.98%
Additional Links:
Companies Related to AEterna Zentaris:

Analyst Ratings

Consensus Ratings for AEterna Zentaris (NASDAQ:AEZS) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.83 (133.83% upside)

Analysts' Ratings History for AEterna Zentaris (NASDAQ:AEZS)
Show:
DateFirmActionRatingPrice TargetDetails
2/14/2017Maxim GroupSet Price TargetBuy$10.00View Rating Details
1/10/2017HC WainwrightReiterated RatingBuy$12.00 -> $7.50View Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for AEterna Zentaris (NASDAQ:AEZS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2016Q415($1.30)($1.46)ViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)ViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)ViewListenView Earnings Details
5/8/2015($0.10)($0.13)ViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06ViewN/AView Earnings Details
11/4/2014($0.16)($0.20)ViewN/AView Earnings Details
5/8/2014($0.30)($0.08)ViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)
Current Year EPS Consensus Estimate: $-2.38 EPS
Next Year EPS Consensus Estimate: $-0.99 EPS

Dividends

Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
DateHeadline
News IconAEterna Zentaris Inc. (NASDAQ:AEZS) Quarterly EPS At $-0.31 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - February 18 at 3:20 PM
streetinsider.com logoAeterna Zentaris (AEZS) Reports Zoptrex Presentation in Prostate Cancer at GenitourinaryCancers Symposium (NASDAQ:AEZS)
www.streetinsider.com - February 15 at 1:41 AM
4-traders.com logoAeterna Zentaris : Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium (NASDAQ:AEZS)
www.4-traders.com - February 15 at 1:41 AM
seekingalpha.com logoAEterna Zentaris (AEZS) Presents at 19th Annual BIO CEO & Investor Conference (NASDAQ:AEZS)
seekingalpha.com - February 15 at 1:41 AM
streetinsider.com logoAeterna Zentaris (AEZS) Reports Zoptrex Presentation in Prostate Cancer at GenitourinaryCancers Symposium - StreetInsider.com (NASDAQ:AEZS)
www.streetinsider.com - February 14 at 8:38 PM
finance.yahoo.com logoAeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium (NASDAQ:AEZS)
finance.yahoo.com - February 14 at 8:38 PM
smarteranalyst.com logoAEterna Zentaris Inc. (USA) (AEZS): Macrilen gets an "A" - Maxim ... - Smarter Analyst (NASDAQ:AEZS)
www.smarteranalyst.com - February 14 at 3:37 PM
News IconBurning Stock on the move: Aeterna Zentaris Inc. (NASDAQ:AEZS) - HugoPress (NASDAQ:AEZS)
hugopress.com - February 14 at 3:37 PM
smarteranalyst.com logoStock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA) Announces Plans to Pursue FDA Registration of Macrilen - Smarter Analyst (NASDAQ:AEZS)
www.smarteranalyst.com - February 13 at 8:37 PM
streetinsider.com logoAeterna Zentaris (AEZS) to Pursue FDA Registration of Macrilen - StreetInsider.com (NASDAQ:AEZS)
www.streetinsider.com - February 13 at 3:33 PM
finance.yahoo.com logo7:31 am Aeterna Zentaris announces that FDA has agreed to consider its conclusions regarding the co's Phase 3 trial of Macrilen during a Type A meeting, which is currently being scheduled (NASDAQ:AEZS)
finance.yahoo.com - February 13 at 3:33 PM
News IconAEterna Zentaris Inc. (NASDAQ:AEZS) Daily Sentiment Score At 0.218 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - February 6 at 3:26 PM
News IconFeatured Stock: AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) - Post Registrar (NASDAQ:AEZS)
postregistrar.com - February 3 at 1:26 AM
us.rd.yahoo.com logo5:33 pm Aeterna Zentaris completed Zoptrex pivotal phase 3 clinical trial in advanced endometrial cancer; expects to report top-line results in April 2017 (NASDAQ:AEZS)
us.rd.yahoo.com - February 1 at 3:28 PM
finance.yahoo.com logoDrug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals (NASDAQ:AEZS)
finance.yahoo.com - February 1 at 3:28 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About AEterna Zentaris Inc. (NASDAQ:AEZS)? - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 31 at 3:31 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About AEterna Zentaris Inc. (NASDAQ:AEZS)? - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 31 at 3:31 PM
News IconStock Vacillating as Volatility Hits a High Point For Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 31 at 3:31 PM
News IconStock Vacillating as Volatility Hits a High Point For Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 31 at 3:31 PM
smarteranalyst.com logoMaxim Chimes In on AEterna Zentaris Inc. (USA) (AEZS) as Zoptrex Completes Enrollment - Smarter Analyst (NASDAQ:AEZS)
www.smarteranalyst.com - January 31 at 3:31 PM
smarteranalyst.com logoMaxim Chimes In on AEterna Zentaris Inc. (USA) (AEZS) as Zoptrex Completes Enrollment - Smarter Analyst (NASDAQ:AEZS)
www.smarteranalyst.com - January 31 at 3:31 PM
News IconExpectations Run High At AEterna Zentaris Inc. (USA) (AEZS) As Two New Drugs Enter Final Testing Phases (NASDAQ:AEZS)
feedproxy.google.com - January 31 at 8:26 AM
smarteranalyst.com logoStock Update (NASDAQ:AEZS): AEterna Zentaris Inc. (USA ... - Smarter Analyst (NASDAQ:AEZS)
www.smarteranalyst.com - January 31 at 1:38 AM
finance.yahoo.com logoAeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer ... - Yahoo Finance (NASDAQ:AEZS)
finance.yahoo.com - January 30 at 8:36 PM
News IconWhat are Research Firms Saying About AEterna Zentaris Inc. (NASDAQ:AEZS)? - Aiken Advocate (NASDAQ:AEZS)
aikenadvocate.com - January 30 at 8:36 PM
feeds.reuters.com logoBRIEF-Aeterna Zentaris completes Zoptrex(tm) pivotal Phase 3 clinical trial in advanced endometrial cancer (NASDAQ:AEZS)
feeds.reuters.com - January 30 at 6:29 PM
News IconPrimed for Breakout or Bust? A look at Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 30 at 3:33 PM
News IconSadif Issues Summary Due Diligence Report on AEterna Zentaris ... - Nelson Research (NASDAQ:AEZS)
nelsonobserver.com - January 29 at 2:05 AM
News IconQuarterly EPS Of AEterna Zentaris Inc. (NASDAQ:AEZS) Set At $-0.31 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - January 28 at 3:22 PM
News IconPrepping for a Big Move? Share Update on Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 27 at 3:48 PM
News IconAEterna Zentaris Inc. (NASDAQ:AEZS) Bearish Target At $10 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - January 25 at 8:28 PM
News IconBrokers Release Average Price Target Of 4.91 On AEterna Zentaris Inc. (AEZS) - UK Market News (NASDAQ:AEZS)
www.ukmarketnews.co.uk - January 24 at 3:42 PM
News IconEarnings in Full Force, Analysts Take Aim at AEterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 24 at 3:42 PM
News IconSell-side is Weighing in on AEterna Zentaris Inc. (NASDAQ:AEZS) Earnings & Targets - Aiken Advocate (NASDAQ:AEZS)
aikenadvocate.com - January 24 at 1:25 AM
News IconPriming The Pump: Stock Volatility Spotted in Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 23 at 3:23 PM
News IconAmplified Volatility Spotted in Shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 20 at 8:28 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 18 at 8:52 PM
News IconMarching to the Beat of Their Own Drum, Update on Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 18 at 3:50 PM
News IconPumping the Brakes as Stock Dragged Lower Mid-Session: Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 18 at 3:50 PM
finance.yahoo.com logoBiotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris (NASDAQ:AEZS)
finance.yahoo.com - January 18 at 3:50 PM
News IconAre These Shares a Bargain: Update on Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 17 at 9:01 PM
News IconInvestors Priming the Pump as Stock Reaches Most Volatile List: Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 17 at 9:01 PM
News IconBoom or Bust? Is there any value in Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 17 at 9:01 PM
News IconAEterna Zentaris Inc. (NASDAQ:AEZS) Daily Sentiment Score At 0.109 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - January 17 at 9:01 PM
News IconWill The Needle Move For AEterna Zentaris Inc. (NASDAQ:AEZS) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 17 at 9:01 PM
News IconStock Mounting Higher in Afternoon Session: Aeterna Zentaris Inc. (NASDAQ:AEZS) - Wall Street Beacon (NASDAQ:AEZS)
wsbeacon.com - January 17 at 9:01 PM
smarteranalyst.com logoMaxim Boosts Price Target for AEterna Zentaris Inc. (USA) (AEZS); Shares Rose 11% (NASDAQ:AEZS)
www.smarteranalyst.com - January 17 at 3:59 PM
News IconAnalysts Take the Wheel on AEterna Zentaris Inc. (NASDAQ:AEZS) Shares and Where They Might Be Headed - Aiken Advocate (NASDAQ:AEZS)
aikenadvocate.com - January 16 at 8:25 PM
News IconTop Stock With Upside & Growth Potential: Aeterna Zentaris Inc. (NASDAQ:AEZS) - Prospect Journal (NASDAQ:AEZS)
prospectjournal.com - January 16 at 8:25 PM
News IconAEterna Zentaris Inc. (NASDAQ:AEZS) Quarterly EPS Set At $-0.31 - Stock Observer (NASDAQ:AEZS)
www.thestockobserver.com - January 14 at 3:22 PM

Social

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?

3 analysts have issued 1 year price targets for AEterna Zentaris' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate AEterna Zentaris' share price to reach $7.83 in the next twelve months.

Who owns AEterna Zentaris stock?

AEterna Zentaris' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.64%).

Who sold AEterna Zentaris stock? Who is selling AEterna Zentaris stock?

AEterna Zentaris' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AEterna Zentaris stock cost?

One share of AEterna Zentaris stock can currently be purchased for approximately $3.35.

AEterna Zentaris (NASDAQ:AEZS) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Earnings History Chart

Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Dividend History Chart

Dividend Payments by Quarter for AEterna Zentaris (NASDAQ:AEZS)

Last Updated on 2/20/2017 by MarketBeat.com Staff